Amarantus Bioscience Holdings, Inc. (OTCMKTS:AMBS) Attempts a Return

After several attempts, Amarantus Bioscience Holdings, Inc. (OTCMKTS:AMBS) seems to be ready to make claims for higher levels. The pharmaceutical ticker grew by more than 34% on Thursday, reaching $0.059 on trading volumes above $757,000. AMBS disappeared for a while, after its promotions ended in mid-June, replaced by other pharmaceutical tickers.

But several press releases indicated that AMBS is closer to marketing a specialized ophthalmology drug, and the latest upward trend has lasted a bit longer. Still, AMBS is correcting regularly, so the gain of a third may be a temporary event.

Otherwise, AMBS is still listed in the development stage, and still announcing its intentions to treat significant diseases of the nervous system. This has led to the latest financial filing, containing:

• $67,061 cash

• $1.2 million total assets

• $5.57 million total current liabilities

• $900,985 quarterly net loss

• $15.2 million net loss since inception

AMBS is still the typical pharmaceutical developer, strongly pressured by debt and losses. Still, for the stock price hopeful future developments are always positive news that create loyalty among investors. Expectations of performance help to lift up pharmaceutical stocks.

The only problem is that once disappointment settles in, or a piece of bad news is revealed, the stock drops often like a rock.

In the past months, one of the tickers with a strong following was Advanced Cell Technology, Inc. (OTCBB:ACTC), which happens to be in a close price range to AMBS. Currently, ACTC is mostly sliding slowly, after deflating from a more active period with PR promises and promotions. ACTC seems to be recovering after reaching a relative bottom at 5 cents, and for now the ticker marked two days of tentative buying.

Skyline Medical, Inc. (OTCMKTS:SKLN) is among the intriguing stocks in the sector, currently hanging around 35 cents on tentative selling of around $200,000. But the main reason behind the 68% growth in the past weeks was a promotion, with the last email landing on August 27th. So for now SKLN is living in a precarious period, with a possible correction on a lack of investor interest.

If you want to have another take of AMBS, keep in mind how much pharmaceutical stocks tend to move backward and avoid investing unaffordable sums, to be prepared for the corrections that this ticker is capable of .